연구성과로 돌아가기
2021 연구자 정보 (129 / 1146)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Author Name | 제1저자 여부 | 교신저자 여부 | Address | ResearcherID | ORCID | Paper Title | WoS Edition | 최상위 JCR(%) | WoS Category | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
|
Musso, Maurizio (Musso, M) |
La Maddalena Casa Cura, Palermo, Italy |
|
|
[JCR상위 4.5] Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial | SCIE | 4.5 | HEMATOLOGY;ONCOLOGY | fravandi@mdanderson.org; | ||
|
Pierdomenico, Francesca (Pierdomenico, F) |
Portuguese Inst Oncol Lisbon, Lisbon, Portugal |
|
|
[JCR상위 4.5] Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial | SCIE | 4.5 | HEMATOLOGY;ONCOLOGY | fravandi@mdanderson.org; | ||
|
Pocock, Christopher (Pocock, C) |
Kent & Canterbury Hosp, Canterbury, Kent, England |
|
|
[JCR상위 4.5] Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial | SCIE | 4.5 | HEMATOLOGY;ONCOLOGY | fravandi@mdanderson.org; | ||
|
Ravandi, Farhad (Ravandi, F) |
제1저자 | 교신저자 | Univ Texas MD Anderson Canc Ctr, Dept Leukemia, 1515 Holcombe Blvd, Houston, TX 77030 USA |
GOH-3538-2022 Ravandi, Farhad |
0000-0002-7621-377X Ravandi, Farhad |
[JCR상위 4.5] Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial | SCIE | 4.5 | HEMATOLOGY;ONCOLOGY | fravandi@mdanderson.org; |
|
Roboz, Gail J. (Roboz, GJ) |
Weill Cornell Med, New York, NY USA NewYork Presbyterian Hosp, New York, NY USA |
|
|
[JCR상위 4.5] Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial | SCIE | 4.5 | HEMATOLOGY;ONCOLOGY | fravandi@mdanderson.org; | ||
|
Safah, Hana (Safah, H) |
Tulane Univ, Hlth Sci Ctr, New Orleans, LA USA |
|
|
[JCR상위 4.5] Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial | SCIE | 4.5 | HEMATOLOGY;ONCOLOGY | fravandi@mdanderson.org; | ||
|
Sayar, Hamid (Sayar, H) |
Indiana Univ, Canc Ctr, Indianapolis, IN USA |
|
|
[JCR상위 4.5] Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial | SCIE | 4.5 | HEMATOLOGY;ONCOLOGY | fravandi@mdanderson.org; | ||
|
Selleslag, Dominik (Selleslag, D) |
AZ Sint Jan Brugge Oostende AV, Brugge, Belgium |
|
|
[JCR상위 4.5] Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial | SCIE | 4.5 | HEMATOLOGY;ONCOLOGY | fravandi@mdanderson.org; | ||
|
Skikne, Barry (Skikne, B) |
Univ Kansas, Med Ctr, Kansas City, KS 66103 USA Bristol Myers Squibb, Princeton, NJ USA |
|
|
[JCR상위 4.5] Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial | SCIE | 4.5 | HEMATOLOGY;ONCOLOGY | fravandi@mdanderson.org; | ||
|
Tse, William (Tse, W) |
Univ Louisville, Sch Med, Louisville, KY 40292 USA |
|
|
[JCR상위 4.5] Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial | SCIE | 4.5 | HEMATOLOGY;ONCOLOGY | fravandi@mdanderson.org; | ||
|
Wei, Andrew H. (Wei, AH) |
Alfred Hosp, Dept Clin Haematol, Melbourne, Vic, Australia Mona Sh Univ, Australian Ctr Blood Dis, Melbourne, Vic, Australia |
F-3707-2012 Wei, Andrew |
0000-0002-7514-3298 Wei, Andrew |
[JCR상위 4.5] Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial | SCIE | 4.5 | HEMATOLOGY;ONCOLOGY | fravandi@mdanderson.org; | ||
|
Zhong, Jianhua (Zhong, JH) |
Bristol Myers Squibb, Princeton, NJ USA |
|
|
[JCR상위 4.5] Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial | SCIE | 4.5 | HEMATOLOGY;ONCOLOGY | fravandi@mdanderson.org; | ||
|
Islam, Md Ariful (Islam, MA) |
Seoul Natl Univ, Sch Biol Sci, Seoul 08826, South Korea North South Univ, Sch Hlth & Life Sci, Dept Pharmaceut Sci, Dhaka 1229, Bangladesh |
IZE-2734-2023 Islam, Md Ariful |
0000-0003-0995-2166 Islam, Md Ariful |
[JCR상위 4.6] Dysfunction of NMDA receptors in neuronal models of an autism spectrum disorder patient with a DSCAM mutation and in Dscam-knockout mice | SCIE | 4.6 | BIOCHEMISTRY & MOLECULAR BIOLOGY;NEUROSCIENCES;PSYCHIATRY | irislkm@knu.ac.kr;leeja@hnu.kr;kaang@snu.ac.kr; | ||
|
Jo, Danbi (Jo, D) |
Chonnam Natl Univ, BioMed Sci Grad Program BMSGP, Hwasun 58128, Jeollanam Do, South Korea Chonnam Natl Univ, Dept Anat, Med Sch, Hwasun 58128, Jeollanam Do, South Korea |
|
|
[JCR상위 4.6] Obesity-linked circular RNA circTshz2-2 regulates the neuronal cell cycle and spatial memory in the brain | SCIE | 4.6 | BIOCHEMISTRY & MOLECULAR BIOLOGY;NEUROSCIENCES;PSYCHIATRY | juhyunsong@chonnam.ac.kr;ykk@jnu.ac.kr; | ||
|
Kim, Chul Hoon (Kim, CH) |
Yonsei Univ, Dept Pharmacol, Coll Med, Seoul 03722, South Korea |
|
0000-0002-7360-429X Kim, Chul Hoon |
[JCR상위 4.6] Dysfunction of NMDA receptors in neuronal models of an autism spectrum disorder patient with a DSCAM mutation and in Dscam-knockout mice | SCIE | 4.6 | BIOCHEMISTRY & MOLECULAR BIOLOGY;NEUROSCIENCES;PSYCHIATRY | irislkm@knu.ac.kr;leeja@hnu.kr;kaang@snu.ac.kr; |
페이지 이동: